
    
      The duration of the trial will be up to approximately 122 weeks. This will include a 1-week
      screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week
      placebo run-in period, a 104-week double-blind, active comparator-controlled treatment
      period, and a post-treatment telephone contact 14 days after the last dose of study drug.
    
  